2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123681
    R 57720 98164-11-5 98%
    R 57720 is an antiepileptic agent that exhibits dose-dependent anticonvulsant activity across multiple postnatal rat age groups. R 57720 inhibits severe generalized tonic-clonic seizures induced by Pentylenetetrazol. R 57720 can be used for epilepsy research.
    R 57720
  • HY-123704
    CGS-12066 maleate 1350965-83-1 98%
    CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT1A , 5-HT1B ,5-HT1C and 5-HT1D with pEC50 values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease.
    CGS-12066 maleate
  • HY-123743
    JNJ-42314415 1334165-90-0 98%
    JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively.
    JNJ-42314415
  • HY-123745
    Aβ aggregation-IN-6 439932-74-8 98%
    Aβ aggregation-IN-6 is an Aβ aggregation inhibitor with ~60-70% inhibition of Aβ17-40 aggregation. Aβ aggregation-IN-6 stabilizes Aβ dimer assembly, binds to Aβ steric-zipper assembly. Aβ aggregation-IN-6 can be used for the research of alzheimer's disease.
    Aβ aggregation-IN-6
  • HY-123778
    VU6007678 2222737-15-5 98%
    VU6007678 is a CNS-penetrant muscarinic acetylcholine receptor (mAChR) modulator. VU6007678 potentiates acetylcholine-mediated signaling at human M1, M3, M5 and rat M1, M3, M4, M5 muscarinic acetylcholine receptors. VU6007678 is applicable to research related to Alzheimer's disease, schizophrenia, and ischemic stroke.
    VU6007678
  • HY-123807
    JNJ-5234801 426227-09-0 98%
    JNJ-5234801 is an orally active anxiolytic that targets the 5-HT2 receptor. JNJ-5234801 increases water intake and reduces alcohol preference in rats. JNJ-5234801 could be used in studies on anxiety and alcoholism.
    JNJ-5234801
  • HY-123836
    MK-7288 936626-07-2 98%
    MK-7288 is a histamine H3 receptor inverse agonist. MK-7288 can prolong sleep latency in the Maintain Wake Test (MWT). MK-7288 can be used in research on obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS).
    MK-7288
  • HY-12383S
    Pelubiprofen-13C,d3 98%
    Pelubiprofen-13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects.
    Pelubiprofen-13C,d3
  • HY-123852
    PF-06764427 1842371-08-7 98%
    PF-06764427 is a selective M1 muscarinic acetylcholine receptor positive allosteric modulator. PF-06764427 exhibits robust M1 agonist activity. PF-06764427 can be used in the research of Alzheimer's disease and schizophrenia.
    PF-06764427
  • HY-123858
    VU6001221 2002495-17-0 98%
    VU6001221 is a blood-brain barrier permeable Choline Transporter (CHT) inhibitor (IC50 = 270 nM). VU6001221 increases the likelihood of extracellular choline elevation activating synaptic α7 nicotine ACh receptors. VU6001221 attenuates potassium-induced ACh levels in the prefrontal cortex.
    VU6001221
  • HY-123859
    SR-2890 1454584-91-8 98%
    SR-2890 is a highly selective, ATP-competitive inhibitor of casein kinase CK1δ and CK1ε, with IC50 values ​​of 4 nM and 44 nM, respectively, and a Ki of 14 nM for CK1δ. SR-2890 exhibits antiproliferative effects. SR-2890 blocks the serine/threonine kinase activity of CK1δ and weakly inhibits a few off-target kinases such as FLT3, CDK4. SR-2890 has an oral bioavailability of 10% and a blood-brain barrier penetration rate of <1%. SR-2890 demonstrates stable in vitro metabolism and favorable in vivo pharmacokinetic properties, effectively inhibiting the growth of human A375 melanoma cells. SR-2890 can be used in melanoma research and is also a useful compound for studying CK1δ/ε-related diseases such as Alzheimer's disease.
    SR-2890
  • HY-123874
    BMS-952048 1375751-32-8 98%
    BMS-952048 is a positive allosteric modulator of mGluR5 with an EC50 of 10 nM.
    BMS-952048
  • HY-123889
    VK4-116 1982347-43-2 98%
    VK4-116 (Compound 19) is a selective Dopamine D3 receptor (D3R) antagonist with a Ki of 6.84 nM.VK4-116 significantly inhibits Oxycodone-induced hyperlocomotion and locomotor sensitization in mouse models. VK4-116 with pretreatment also inhibits the acquisition of Oxycodone-induced conditioned place preference (CPP) in rat models.
    VK4-116
  • HY-12390A
    Lofepramine hydrochloride 26786-32-3 98%
    Lofepramine (Lopramine) is a modified tricyclic and orally active antidepressant. Lofepramine inhibits the uptake of Noradrenaline (NA) (HY-13715) and 5-hydroxytryptamine (5-HT) with IC50s of 2.7 μM and 11 μM, respectively. Lofepramine exerts its antidepressant activity by promoting noradrenergic neurotransmission. Lofepramine also enhances serotonergic neurotransmission by inhibiting neuronal uptake of 5-HT and tryptophan pyrrolase. Lofepramine exhibits significant anxiolytic properties. .
    Lofepramine hydrochloride
  • HY-12391A
    Dibenzepine hydrochloride 315-80-0 98%
    Dibenzepine (hydrochloride) is a tricyclic antidepressant agent. Dibenzepine (hydrochloride) can be studied in research on psychotic disorders.
    Dibenzepine hydrochloride
  • HY-123928
    Contilisant 2135615-68-6 98%
    Contilisant is a permeable antioxidant and neuroprotectant agent. Contilisant exhibits high nM affinity at H3R. Contilisant inhibits monoamine oxidases and cholinesterases. Contilisant has a binding affinity of 65.23 nM towards hS1R. Contilisant can significantly restore cognitive deficit induced by Aβ1-42 in the radial maze assay of Alzheimer’s animal model.
    Contilisant
  • HY-12392A
    Iprindole hydrochloride 20432-64-8 98%
    Iprindole hydrochloride, an opioid receptor agonist, is a tricyclic antidepressant. Iprindole hydrochloride shortens the immobility time in mice forced swimming test, which can be reversed by the opiate antagonist Naloxone (HY-17417A). Iprindole hydrochloride induces lamellar body formation but devoid of lamellar bodies. Iprindole hydrochloride can be used for the research of depression.
    Iprindole hydrochloride
  • HY-123933
    TTGM 5826 330471-93-7 98%
    TTGM 5826 is a tissue transglutaminase (tTG) inhibitor with an EC50 of 20 μM. TTGM 5826 stabilizes the open conformation of tTG that exhibits protein cross-linking activity, and acts as a competitive inhibitor of tTG-mediated cross-linking activity. TTGM 5826 inhibits the transformed phenotypes of breast cancer cells, brain cancer cells and glioma stem cells. TTGM 5826 can be used in the research of breast cancer, glioblastoma, pancreatic cancer and glioma stem cell-related tumors.
    TTGM 5826
  • HY-123958
    SB772077B 785774-34-7 98%
    SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
    SB772077B
  • HY-123970
    ISO-92 899433-49-9 98%
    ISO-92 in an inhibitor of MIF. ISO-92 selectively inhibits MIF inflammatory activity with an IC50 of 550 nM. ISO-92 inhibits hypoxia-induced proliferation of CCL-210 cell line dose-dependently. ISO-92 significantly reduces the thickness of pulmonary vascular wall in mouse hypoxia models. ISO-92 can be studied in inflammatory and neurological research.
    ISO-92
Cat. No. Product Name / Synonyms Application Reactivity